Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gregory Guzauskas"'
BACKGROUND: The EF-14 trial was the first randomized controlled trial to report a survival benefit for newly diagnosed GBM patients in more than a decade with a survival rate greater than 10% at 5-years. A post hoc subgroup analysis of the elderly (>
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e7b199cc4ea797b2d8f5704b026ce1
https://europepmc.org/articles/PMC6217141/
https://europepmc.org/articles/PMC6217141/
BACKGROUND: TTFields plus TMZ treatment significantly increased five-year overall survival results compared to TMZ alone in all patients in the EF-14 trial, with the subgroup of patients age 65 and older showing the greatest survival benefit (hazard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a525ac0a04fc0c292d17a4fa565cfaf
https://europepmc.org/articles/PMC6217146/
https://europepmc.org/articles/PMC6217146/
Autor:
Rosa Willock, Quentin M. Anstee, Anthony Hatswell, Vanessa Hebditch, Mzwandile A. Mabhala, Jamie O'Hara, PD Dr. Schattenberg Jörn, Judy Rhys, Manuel Romero-Gómez, Vlad Ratziu, Gregory Guzauskas, Leonardo Ruiz, Alan Finnegan, Thomas Russell, Bengt Jönsson, Ingo Van Thiel, Elisabetta Bugianesi, Tatjana Reic, George Morgan
Publikováno v:
Journal of Hepatology. 70:e35-e36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86570cd78476c9ee6e1270596dfb875f
https://doi.org/10.1016/s0618-8278(19)30064-7
https://doi.org/10.1016/s0618-8278(19)30064-7
